EXPAREL Real-World Data Reveals Significant Opioid Reduction, Lower Medical Costs for Medicare Hip Patients
Summary
Pacira BioSciences announced compelling real-world data for its flagship product, EXPAREL, demonstrating significant reductions in opioid use and total medical costs for Medicare patients undergoing total hip arthroplasty. The study, presented at ASRA, showed EXPAREL was associated with substantially lower opioid consumption, healthcare resource utilization, and overall medical expenses over a 12-month period compared to standard-of-care. This positive data strengthens EXPAREL's value proposition, providing critical evidence for increased adoption among a vulnerable patient population and potentially influencing reimbursement decisions. This development is a positive catalyst for the company, distinct from recent corporate governance issues, and could drive future sales growth.
At the time of this announcement, PCRX was trading at $24.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $992.4M. The 52-week trading range was $18.80 to $27.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.